Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis
Clinical trial NCT04742400 · UNKNOWN
Trial details
- NCT number
- NCT04742400
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-15
- Primary completion
- 2023-06-15
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.